Resultados da busca - Deborah Forst
- Mostrando 1 - 10 resultados de 10
-
1
Low-Grade Gliomas por Deborah Forst, Brian V. Nahed, Jay S. Loeffler, Tracy T. Batchelor
Publicado em 2014Revisão -
2
-
3
Palliative care and end-of-life care in adults with malignant brain tumors por Johan A F Koekkoek, Pim B. van der Meer, Andrea Pace, Caroline Hertler, Rebecca A. Harrison, Heather Leeper, Deborah Forst, Rakesh Jalali, Kathy Oliver, Jennifer Philip, Martin Taphoorn, Linda Dirven, Tobias Walbert
Publicado em 2022Revisão -
4
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells por Philipp Karschnia, Justin T. Jordan, Deborah Forst, Isabel Arrillaga‐Romany, Tracy T. Batchelor, Joachim M. Baehring, Nathan F. Clement, L. Nicolas Gonzalez Castro, Aline Herlopian, Marcela V. Maus, Michaela H. Schwaiblmair, Jacob D. Soumerai, Ronald W. Takvorian, Ephraim P. Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Matthew J. Frigault, Jörg Dietrich
Publicado em 2019Artigo -
5
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis por Benjamin Kasenda, Andrés J.M. Ferreri, Emerenziana Marturano, Deborah Forst, Jacoline E. C. Bromberg, Hervé Ghesquières, Céline Ferlay, Jean‐Yves Blay, Khê Hoang‐Xuan, Elisa Jacobsen Pulczynski, Alexander Fosså, Y. Okoshi, Shigeru Chiba, Kristina Fritsch, Antonio Omuro, Brian Patrick O’Neill, Osnat Bairey, Stefan Schandelmaier, Viktoria Gloy, Neera Bhatnagar, Stefan Haug, Susanne Rahner, Tracy T. Batchelor, Gerald Illerhaus, Matthias Briel
Publicado em 2015Revisão -
6
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations por Priscilla K. Brastianos, Albert E. Kim, Nancy Wang, Eudocia Q. Lee, Jennifer A. Ligibel, Justine V. Cohen, Ugonma Chukwueke, Maura Mahar, Kevin Oh, Michael White, Helen A. Shih, Deborah Forst, Justin F. Gainor, Rebecca S. Heist, Elizabeth R. Gerstner, Tracy T. Batchelor, Donald P. Lawrence, David P. Ryan, A. John Iafrate, Anita Giobbie‐Hurder, Sandro Santagata, Scott L. Carter, Daniel P. Cahill, Ryan J. Sullivan
Publicado em 2021Artigo -
7
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial por Matthew J. Frigault, Jörg Dietrich, Kathleen Gallagher, Mark Roschewski, Justin T. Jordan, Deborah Forst, Scott R. Plotkin, Daniella Cook, Keagan S. Casey, Kevin Lindell, Gabriel D. Depinho, Katelin Katsis, Eva L. Elder, Mark B. Leick, Bryan D. Choi, Nora Horick, Frederic I. Preffer, Meredith Saylor, Steven L. McAfee, Paul V. O’Donnell, Thomas R. Spitzer, Bimalangshu R. Dey, Zachariah DeFilipp, Areej El‐Jawahri, Tracy T. Batchelor, Marcela V. Maus, Yi‐Bin Chen
Publicado em 2022Artigo -
8
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas por Priscilla K. Brastianos, Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy Wang, April F. Eichler, Ugonma Chukwueke, Deborah Forst, Isabel Arrillaga‐Romany, Jörg Dietrich, Zachary Corbin, Jennifer Moliterno, Joachim M. Baehring, Michael G. White, Kevin Lou, Juliana M. Larson, Magali de Sauvage, Kathryn Evancic, Joana L. Mora, Naema Nayyar, Jay S. Loeffler, Kevin Oh, Helen A. Shih, William T. Curry, Daniel P. Cahill, Fred G. Barker, Elizabeth R. Gerstner, Sandro Santagata
Publicado em 2022Artigo -
9
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis por Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Q. Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Forst, April F. Eichler, Beth Overmoyer, Nancy U. Lin, Wendy Y. Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo‐Jack, Michael White, Jörg Dietrich, Naema Nayyar, Albert E. Kim, Christopher Alvarez‐Breckenridge, Maura Mahar, Joana L. Mora, Brian V. Nahed, Pamela S. Jones, Helen A. Shih, Elizabeth R. Gerstner, Anita Giobbie‐Hurder, Scott L. Carter, Kevin Oh, Daniel P. Cahill, Ryan J. Sullivan
Publicado em 2021Artigo -
10
Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma por Mihir Gupta, Joseph D. Bradley, Elie Massaad, Evan Burns, N. Zeke Georgantas, Garrett E. Maron, Julie M. Batten, Aidan Gallagher, Julia Thierauf, Naema Nayyar, Amanda Gordon, SooAe Jones, Michelle Pisapia, Ying Sun, Pamela S. Jones, Fred G. Barker, William T. Curry, Rajiv Gupta, Javier M. Romero, Nancy Wang, Priscilla K. Brastianos, Maria Martinez‐Lage, Kensuke Tateishi, Deborah Forst, Brian V. Nahed, Tracy T. Batchelor, Lauren L. Ritterhouse, Florian Iser, Tobias Keßler, Justin T. Jordan, Jörg Dietrich, Matthew Meyerson, Daniel P. Cahill, Jochen K. Lennerz, Bob S. Carter, Ganesh M. Shankar
Publicado em 2024Artigo
Ferramentas de busca:
Assuntos relacionados
Internal medicine
Medicine
Oncology
Cancer
Cancer research
Immunotherapy
Lymphoma
Primary central nervous system lymphoma
Biology
Central nervous system
Cerebrospinal fluid
Chemotherapy
Chimeric antigen receptor
Clinical trial
Cognition
Cytokine release syndrome
Immunology
Neurocognitive
Nursing
Pathology
Psychiatry
Adverse effect
Brain tumor
Breast cancer
Caregiver burden
Cell cycle
Circulating tumor DNA
Clinical endpoint
Cohort
Cyclin-dependent kinase